GSK plc - 02 Jul 2021 Form 4 Insider Report for CVRx, Inc. (CVRX)

Reporting relationship: 10%+ Owner
Issuer ticker: CVRX
Reported as of: 02 Jul 2021
Net transaction value: +$4,950,000
SEC form: 4
Accepted by SEC: 06 Jul 2021, 16:38:14 UTC
Prior SEC filing: 06 Jul 2021
Next SEC filing: 20 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Victoria Whyte

Key filing fact

GSK plc filed Form 4 for CVRx, Inc. (CVRX) on 06 Jul 2021.

Key facts

This page summarizes GSK plc's Form 4 filing for CVRx, Inc. (CVRX).
13 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 06 Jul 2021, 16:38.

Change

Previous filing in this sequence was filed on 06 Jul 2021.
Current net transaction value: +$4,950,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CVRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,505
Change %: +4.7%
Price
Shares after: 33,316
Date: 02 Jul 2021
Ownership: See Footnote
Footnotes: F2, F4

CVRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +12,979
Change %: +39%
Price
Shares after: 46,295
Date: 02 Jul 2021
Ownership: See Footnote
Footnotes: F2, F4

CVRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +14,917
Change %: +32%
Price
Shares after: 61,212
Date: 02 Jul 2021
Ownership: See Footnote
Footnotes: F2, F4

CVRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +8,380
Change %: +14%
Price
Shares after: 69,592
Date: 02 Jul 2021
Ownership: See Footnote
Footnotes: F2, F4

CVRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +27,345
Change %: +39%
Price
Shares after: 96,937
Date: 02 Jul 2021
Ownership: See Footnote
Footnotes: F2, F4

CVRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +635,646
Change %: +656%
Price
Shares after: 732,583
Date: 02 Jul 2021
Ownership: See Footnote
Footnotes: F3, F4

CVRX transaction

Common Stock

Purchase

Transaction value: $4,950,000
Shares: +275,000
Change %: +38%
Price: $18.00
Shares after: 1,007,583
Date: 02 Jul 2021
Ownership: See Footnote
Footnotes: F1, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CVRX transaction Derivative

Series B-2 Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -59,527
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jul 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 1,505
Exercise price
Footnotes: F2, F4

CVRX transaction Derivative

Series C-2 Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -513,312
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jul 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 12,979
Exercise price
Footnotes: F2, F4

CVRX transaction Derivative

Series D-2 Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -589,939
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jul 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 14,917
Exercise price
Footnotes: F2, F4

CVRX transaction Derivative

Series E-2 Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -331,399
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jul 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 8,380
Exercise price
Footnotes: F2, F4

CVRX transaction Derivative

Series F-2 Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -1,081,434
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jul 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 27,345
Exercise price
Footnotes: F2, F4

CVRX transaction Derivative

Series G Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -10,055,408
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jul 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 635,646
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering.

Footnote F2

The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Footnote F3

The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Footnote F4

The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

Footnote F5

The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.